Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this research is to determine the benefit of pemigatinib in patients with
advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who
have progressed on previous therapy.